Disease management

The AI co-developed with ASX-listed Artrya can outperform the Agatston score in predicting cardiac events.

Also, four tuberculosis screening AI solutions from Asia-Pacific are among those recommended by the World Health Organization.

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

Technological innovation has the power and promise to transform healthcare. This series spotlights companies developing such cutting-edge innovations—ranging from brain-computer and muscle-machine interfaces to 3D-printed breast bioprostheses and beyond.

The wristband is designed to alleviate essential tremors by modulating the nervous system and restoring motor control.

Also, new mobile applications promoting mental wellbeing have been launched.

Julien Payen, cofounder and CEO of Lattice Medical, describes the company's 3D-printed, resorbable breast implant that uses a patient's own fat to regenerate natural breast tissue after a mastectomy.

The funds will be used to increase the company's research and development initiatives and expand its workforce. 

The company will use the funds to speed up the commercialization of BiWaze Clear, scale U.S. sales initiatives, invest in clinical research and increase patient participation.

Also, VUNO has obtained regulatory clearance in South Korea for its AI-based screening solution for kidney failure.